Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Up 290.9% in April

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 90,300 shares, a growth of 290.9% from the March 31st total of 23,100 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily volume of 82,300 shares, the days-to-cover ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

Separately, Benchmark reiterated a “speculative buy” rating and issued a $4.00 target price on shares of Alterity Therapeutics in a research note on Thursday, March 7th.

Alterity Therapeutics Stock Performance

Shares of ATHE traded down $0.07 during mid-day trading on Thursday, reaching $2.26. 24,573 shares of the company’s stock traded hands, compared to its average volume of 77,546. Alterity Therapeutics has a 12 month low of $1.55 and a 12 month high of $5.41. The business’s 50-day moving average price is $1.95 and its 200-day moving average price is $2.18.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.